Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preparation of cell-derived vesicles from eukaryotic and prokaryotic origins for the delivery of biomolecules

  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Smithers, Luke|||0000-0002-4512-9401
  • Cooper, Crystal|||0000-0002-5247-1168
  • Vrielink, Alice|||0000-0001-8197-3725
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Cell membrane-derived vesicles play essential roles in intercellular communication, material transport, and waste disposal. Despite their biomedical and industrial potential, isolating extracellular vesicles from natural sources remains technically challenging, limiting purification efficiency and scalability. This study introduces cell membrane extrusion as an alternative approach to optimize the production of cell membrane-derived vesicles (CSMs), from eukaryotic and prokaryotic cells. CSMs, generated from HeLa and SH-SY5Y cells exhibited a distinctive cup-shaped morphology and sizes of 151.36 ± 72.36 nm, and 416.86 ± 108.49 nm at 20 °C by DLS respectively, showing remarkable thermal stability at 4-70 °C range. Furthermore, loaded vesicles interacted with mammalian cells and achieved successful cargo internalization. CSMs were also produced from E. coli membranes, forming unilamellar vesicles of approximately 100 nm, as observed by Cryo-TEM. These vesicles displayed an inverse correlation between vesicle size and thermal stability and efficient cargo incorporation detected in 85% ± 3% of CSMs. However, under tested conditions, no interaction with prokaryotic cells occurred, and consequently, no delivery of the loaded molecule was observed. Overall, thesefindings highlight the potential of generating cell membrane-derived nanovesicles through extrusion, offering a promising strategy to mimic extracellular vesicles for innovative biomedical and industrial applications, including targeted drug delivery system.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Recombinant vaccines in 2022, a perspective from the cell factory

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80's, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhanced recombinant protein capture, purity and yield from crude bacterial cell extracts by N-Lauroylsarcosine-assisted affinity chromatography

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Background: Recombinant proteins cover a wide range of biomedical, biotechnological, and industrial needs. Although there are diverse available protocols for their purification from cell extracts or from culture media, many proteins of interest such as those containing cationic domains are difficult to purify, a fact that results in low yields of the final functional product. Unfortunately, this issue prevents the further development and industrial or clinical application of these otherwise interesting products. Results: Aiming at improving the purification of such difficult proteins, a novel procedure has been developed based on supplementing crude cell extracts with non-denaturing concentrations of the anionic detergent N-Lauroylsarcosine. The incorporation of this simple step in the downstream pipeline results in a substantial improvement of the protein capture by affinity chromatography, an increase of protein purity and an enhancement of the overall process yield, being the detergent not detectable in the final product. Conclusion: By taking this approach, which represents a smart repurposing of N-Lauroylsarcosine applied to protein downstream, the biological activity of the protein is not affected. Being technologically simple, the N-Lauroylsarcosine-assisted protein purification might represent a critical improvement in recombinant protein production with wide applicability, thus smothering the incorporation of promising proteins into the protein market.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biofabrication of Self-Assembling Covalent Protein Nanoparticles through Histidine-Templated Cysteine Coupling

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Rueda, Ariana|||0000-0001-7588-9279
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez-Alba, Lucía|||0000-0001-7353-1097
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Serna, Naroa|||0000-0001-5682-8198
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Nanoscale protein materials show increasing applications in biotechnology and biomedicine, addressing catalysis, drug delivery, or tissue engineering. Although protein oligomerization is reachable through several engineering approaches, including the use of divalent cations for histidine-rich stretches, the effectiveness of cation-His binding is influenced by protein conformation, media composition, and chelating agents. Thus, looking for powerful, green, cross-linker-free, and transversal oligomerization platforms, we have built a histidine-templated cysteine-coupling concept. On this basis, we have engineered a Cys-containing, H6-derived His-Cys hybrid tag that enables the spontaneous and efficient self-assembling of tagged proteins into monodisperse nanoparticles through a highly ordered covalent binding process. Although the generated nanostructures are supported by disulfide bridge formation and exclusively reversed by reducing agents but not by chelating agents, the presence of cysteine residues does not disrupt the metal-binding abilities of histidine residues within the tag. This fact allows one to combine the one-step IMAC-based protein purification and, also, the Zn2+-induced formation of higher-order microparticulate materials as nanoparticle-releasing protein-only depots. The dual mode of cross-molecular interactivity shown by the hybrid tag and the structural robustness and stability of the resulting nanoparticles offer wide applicability of the green biofabrication concept proposed here for the further development of clinically usable protein materials.